Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07211607) titled 'I.V. Selonabant in Healthy Adult Subjects' on Sept. 29.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Anebulo Pharmaceuticals
Condition:
Healthy Volunteers
Intervention:
Drug: selonabant
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: September 22, 2025
Target Sample Size: 40
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07211607
Published by...